Navigation Links
Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
Date:10/16/2008

Collaboration Brings Cooperative Group Level Radiation Therapy Trials to US

Oncology Affiliates' Patients for First Time

HOUSTON, Oct. 16 /PRNewswire/ -- The Radiation Therapy Oncology Group (RTOG) and US Oncology, Inc. today announced they have entered into a collaboration to increase patient access to national cancer clinical trials with a radiation focus in the community setting.

The collaboration means patients receiving cancer care at practices affiliated with US Oncology have access to RTOG trials for disease sites including brain, head & neck, lung, gastrointestinal, genitourinary, cervix, and breast cancers. RTOG trials focus on testing the integration of radiation therapy with new systemic therapies and surgery.

The collaboration also marks the first time US Oncology, as a network of member practices, has participated in cooperative group trials in radiation oncology. In addition, US Oncology is the first multi-state, national organization to become an affiliate member of RTOG. Current members include large regional practices and academic practices with several facilities in metropolitan areas.

"Our collaboration with US Oncology and its network of member practices is attractive due to the organization's strong commitment to clinical trial participation, leadership and accrual," said Walter Curran, MD, Group Chairman of RTOG and professor and chairman of the Department of Radiation Oncology of Emory University School of Medicine. Dr. Curran also serves as Chief Medical Officer of the Winship Cancer Center at Emory University. "We were confident their track record as a multi-site organization with significant accruals in a variety of clinical trials would be a good fit," said Dr. Curran.

Following infrastructure development to centralize the IRB, data collection, reporting, credentialing and quality assurance to operate as a network, US Oncology was granted affiliate member status in the RTOG late last
'/>"/>

SOURCE US Oncology
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
3. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Synchrotron radiation illuminates how babies protective bubble bursts
8. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
9. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
10. FDA Clears Expanded Use of Xofts Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications
11. CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 Vestiage, Inc. (stock symbol ... on science-based research and development, sales and marketing ... nutraceuticals, announced today that it is awarding exclusive ... sale of Reluma Skin Illuminating Facial Care. Qualified ... by sending an email to info(at)vestiageinc(dot)com and putting ...
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. (Nasdaq: ... focused on obtaining FDA clearance and commercializing its rapid, ... the pricing of an underwritten public offering of 10,000,000 ... purchase 3,500,000 shares of its common stock at an ... public offering price of $1.25 per share and related ...
(Date:5/23/2013)... May 23, 2013 Patheon Inc ... services to the global pharmaceutical industry, will host a ... Approaches to Testing” on Tuesday, June 4, 2013 at ... manufacturers are required to comply with regulations for cleaning ... with limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... MA (PRWEB) May 23, 2013 ... inch wide and provide 15 mm travel range ... The small dimensions make these new positioners ... confined spaces. A vacuum rated version is also ... Drawings, specifications and datasheets can be found at: ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2
... 1 PSKW, LLC, a New Jersey-based,leading provider ... today that it has significantly expanded the scope ... the Supreme Court of the State,of New York, ... Inc.,("McKesson"), a wholly-owned subsidiary of McKesson Corporation. PSKW ...
... China, Sept. 1 /Xinhua-PRNewswire-FirstCall/ -- China,Pharma Holdings, ... which,develops, manufactures, and markets generic and branded ... the Susquehanna Financial,Group, LLP (SIG)"Beijing Management Summit" ... the 12th of September 2008., Attending ...
... , With some 20,000 UK children with ... year, new guidance from the National Institute for ... the way children,manage their diabetes, granting more freedom ... insulin pump therapy. The new,recommendations finally acknowledge key ...
Cached Biology Technology:PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKesson's Patent Application 2British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 2British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 3British School Kids With Diabetes Gain First Time Freedom From Injections With New Insulin Pump Guidelines 4
(Date:5/23/2013)... treating cerebral palsy with autologous cord blood. Following a ... old boy had been in a persistent vegetative state ... after treatment with the cord blood containing stem cells, ... child learned to speak simple sentences and to move. ... dispel the long-held doubts about the effectiveness of the ...
(Date:5/23/2013)... world,s largest and fastest growing open-access publishers, announces ... in Bioengineering and Biotechnology . , A ... in Bioengineering and Biotechnology will provide a ... and biotechnology research to be disseminated and discussed. ... will provide an open-science and interactive web ...
(Date:5/23/2013)... age when microbial pathogens are growing increasingly resistant to ... team of Wisconsin scientists has synthesized a potent new ... cause staph infections. , Writing online in the ... led by University of Wisconsin-Madison chemistry Professor Helen Blackwell ... behavior of Staphylococcus aureus , a bacterium at ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2
... YORK Computed Tomography (CT) scans are an increasingly used ... organ or tissue. The value of CT scanning to diagnose ... these scans being used too frequently, in some cases unnecessarily" ... scans over the course of a persons life" In ...
... Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused ... diseases of aging, announced today that findings in the ... candidates that offer a promising, new approach to treating ... SIRT1, a gene that controls the aging process. ...
... of nanotechnologys potential risks growing" If so, ... newspapers and newswiresenvironmental and consumer organizations, scientists, law ... broadcast journalists decide to cover a nanotechnology story, ... and television correspondents face special challenges reporting on ...
Cached Biology News:Columbia researchers: Growth of CT scan use may lead to significant public health problem 2Columbia researchers: Growth of CT scan use may lead to significant public health problem 3Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging 2Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging 3Nanotechnology and the media: The inside story 2
... K-12 strain ideally suited as an initial ... efficiency, blue/white screening capability (with appropriate plasmids) ... high yields of excellent quality plasmid DNA. ... useful as a stringent host due to ...
... kit contains all the reagents required for ... c reductase activity in cell and tissue ... (ER)]. It has been tested on samples ... kidney, brain, spleen, and heart muscle from ...
... an automated, confocal, real-time, single cell kinetic ... integrated into a single, compact unit. ... high-resolution, automated confocal imaging with sophisticated imaging ... assays. The system allows the user to ...
... Invitrogen makes blotting of E-PAGE Gels easier ... fiber blotting pad and several types of ... fit 8.6 cm x 13.5 cm E-PAGE ... membranes are designed for western transfer of ...
Biology Products: